The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 68.00 (0.55%)
Spread: 2.00 (0.016%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

Wed, 27th Mar 2024 08:02

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

"Traders are confident in the upcoming rate cuts. Robust US growth doesn't scare as long as inflation continues to ease. And even the recent rise in inflation doesn't concern much as it is believed to be temporary," said Swissquote Bank analyst Ipek Ozkardeskaya.

"As such, the Fed is expected to cut rates in June for the first time."

The latest core personal consumption expenditures reading, the Fed's preferred inflation gauge, is released on Friday.

Investors also digested some industrial data from China. The yen, meanwhile, tumbled as it continues to struggle despite the Bank of Japan's historic rate hike last week.

In early corporate news, Diploma announced the GBP236 million proposed acquisition of aerospace specialty fasteners distributor Peerless Aerospace Fastener, while AstraZeneca announced two drug approvals in Japan.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: down 0.1% at 7,920.80

----------

Hang Seng: down 1.4% at 16,394.79

Nikkei 225: closed up 0.9% at 40,762.73

S&P/ASX 200: closed up 0.5% at 7,819.60

----------

DJIA: closed down 31.31 points, 0.1%, at 39,282.33

S&P 500: closed down 14.61 points, 0.3%, at 5,203.58

Nasdaq Composite: closed down 68.77 points, 0.4%, to 16,315.70

----------

EUR: down at USD1.0827 (USD1.0828)

GBP: up at USD1.2628 (USD1.2626)

USD: up at JPY151.70 (JPY151.50)

Gold: up at USD2,179.73 per ounce (USD2,176.17)

(Brent): down at USD84.78 a barrel (USD85.94)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

10:00 GMT eurozone consumer confidence

10:00 GMT eurozone economic sentiment index

14:30 GMT US EIA crude oil stocks

22:00 GMT US Federal Reserve Governor Christopher Waller speaks

----------

The regulator of the UK's oil and gas companies has said that they need to take action to set themselves on a path to reducing emissions and warned it could block developments if they did not take reasonable steps. The North Sea Transition Authority said that a plan it published on Wednesday highlights "the need for action across the board on production decarbonisation". It said that it would work with oil and gas developers, but if they did not take steps it thought necessary it might not approve their applications. Despite falls in recent years, the production of oil and gas in the UK contributes around 3% of the UK's total greenhouse gas emissions. That is not taking into account the emissions produced when that oil and gas is burnt. This comes partly from the energy that oil rigs and other operations use to transport staff and equipment, pump up oil and much else beside. But it also comes from practices such as venting or flaring – the process of either releasing unwanted gas into the atmosphere, or burning it on site without utilising the energy that it could produce.

----------

The yen hit a 34-year low against the dollar on Wednesday, just over a week after the Bank of Japan announced a much-anticipated interest rate hike in a shift away from years of ultra-loose monetary policy. The unit weakened to JPY151.97 per dollar, its softest since 1990, raising speculation that authorities will intervene in markets to prop up the currency. But its value soon recovered to levels of around JPY151.72. The drop came after a top central bank official suggested it would continue to pursue an accommodative policy for the time being, echoing previous comments from the BoJ.

----------

BROKER RATING CHANGES

----------

UBS raises Sainsbury's to 'buy' (neutral) - price target 295 (275) pence

----------

COMPANIES - FTSE 100

----------

Diploma announced the proposed acquisition of Peerless Aerospace Fastener, a distributor of specialty fasteners into the US and European aerospace markets, for around GBP236 million. The London-based supplier of specialised technical products and services said it expects the transaction to complete in the next few weeks, following customary regulatory clearances. Diploma Chief Executive Officer Johnny Thomson commented: "Peerless is an excellent acquisition for Diploma, aligned to our strategy of building high quality, scalable businesses for sustainable organic growth...We know and like the aerospace fasteners market and Peerless significantly extends our US capabilities and adds scale in Europe."

----------

AstraZeneca noted two drug approvals in Japan. In collaboration with Sanofi, the pharmaceutical firm's Beyfortus treatment was approved for the treatment of lower respiratory tract disease caused by respiratory syncytial virus in infants and children. AstraZeneca expects Beyfortus to be available for the upcoming 2024/25 RSV season, in line with existing Japanese guidelines. Meanwhile, its Truqap treatment in combination with Faslodex has also been approved in Japan for the treatment of adult patients with various forms of breast cancer after treatment with hormone therapy.

----------

COMPANIES - FTSE 250

----------

Playtech reported profit in 2023 more than doubled, and it said it has made a decent start to 2024. Playtech's pretax profit in 2023 jumped to EUR235.8 million from EUR95.6 million in 2022, as revenue rose 6.9% to EUR1.71 billion from EUR1.60 billion. The Isle of Man-based gambling software development company said its 2023 performance was ahead of expectations and that it is on track to meet its medium-term targets. It did not declare a dividend, unchanged from a year earlier. Chief Executive Officer Mor Weizer commented: "As well as delivering excellent financial results, the group made important strategic and operational progress, including our expansion across the US, opening a third Live Casino facility in Pennsylvania and taking the number of licences granted to 11 with further applications pending." Playtech said it has made a "solid" start to trading in 2024 and that it remains confident in executing on growth opportunities.

----------

OTHER COMPANIES

----------

S4 Capital reported a narrowed loss in 2023, though revenue fell as the company grappled with tough economic conditions and "client caution". S4 Capital's pretax loss in 2023 narrowed markedly to GBP13.9 million from GBP159.7 million in 2022, although revenue fell 5.7% to GBP1.01 billion from GBP1.07 billion, while total operating expenses fell 17% to GBP853.0 million from GBP1.03 billion. The London-based digital advertising, marketing and technology services firm also announced the appointment of Jean-Benoit Berty as chief operating officer, effective immediately. Executive Chair Martin Sorrell commented: "After our first four strong net revenue growth years, we had a difficult 2023 reflecting challenging global macroeconomic conditions, fears of recession and high interest rates. This resulted in client caution to commit and extended sales cycles, particularly for larger projects, a difficult year for new business, as well as spend reductions from some regional and smaller client relationships." Sorrell added that like-for-like net revenue for 2024 is to be down on 2023, "with a broadly similar overall level of profit performance to 2023". He added: "We remain confident that our talent, business model, strategy and scaled client relationships position us well for above average growth in the longer term, with an emphasis on deploying free cash flow to boost shareowner returns."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.